Aurinia Pharmaceuticals to Announce Q2 Results on August 1, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company, has announced plans to release its financial and operational results for the second quarter of 2024 on August 1, 2024, before the market opens. Following the release, the management team will host a conference call and webcast at 8:30 am ET to discuss the results and provide a business update.

Participants interested in joining the call can dial (866) 682-6100 or (862) 298-0702 for toll-free access in the U.S. and Canada. Additionally, the audio webcast will be available through the company's website, where a replay will also be accessible.

Aurinia Pharmaceuticals is dedicated to developing and delivering treatments for autoimmune diseases with significant unmet needs. In January 2021, Aurinia launched LUPKYNIS® (voclosporin), the first FDA-approved oral medication specifically for treating adult patients with active lupus nephritis. The company operates from its head office in Edmonton, Alberta, with a U.S. commercial office located in Rockville, Maryland, and conducts its development efforts on a global scale.